Skip To Main Content
Shernan G. Holtan on Muck Rack

Shernan G. Holtan

As seen in: Nature, Wiley Online Library, Buffalo Business First, MDEdge, ONCOLOGY journal, OncLive, Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shernan G.

Contact Shernan G., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age

|
By Rohtesh S Mehta, Christopher G. Kanakry, Mariam T. Nawas, Aleksandr Lazaryan, Jennifer A. Kanakry, Shernan G. Holtan, Taha Al-Juhaishi, Anurag Singh Verified, Jennifer N. Saultz, Shannon R McCurdy, Filippo Milano, Joseph Cataquiz Rimando
| Nature Verified
Abstract In allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy), clinicians frequently face a critical choice between a readily available, often younger, haploidentical and a fully matched unrelated donor (MUD). The platform-specific influence of donor age on survival is a critical, unquantified factor that complicates clinical decision-making.
Open in Who Shared Issue with article?

ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device | Bone Marrow Transplantation

|
By Theresa Hahn, Shernan G. Holtan, Philip L McCarthy
| Nature Verified
Physical function can be an independent predictor of cancer survival [1,2,3,4]. Our hypothesis was that physical function measures evaluated before lymphodepletion are independent predictors of CAR-T therapy outcomes, including ICANS and overall survival (OS). This retrospective cohort of 91 NHL CAR-T patients were infused between 2018 and 2023. All patients were referred for a comprehensive physical therapy evaluation from two dedicated TCT physical therapists before infusion as standard-of-care.
Open in Who Shared Issue with article?

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

|
By Rahul Banerjee, Shernan G. Holtan
| ONCOLOGY journal Verified
CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.
Open in Who Shared Issue with article?
See all 9 licensed articles (24 Total)